Pub Date : 2024-06-11DOI: 10.1515/oncologie-2024-0086
Liuyu Ru, Jiwei Zheng
Abstract Immune checkpoint inhibitors (ICIs) promote antitumour immune responses by blocking inhibitory signals expressed by T cells and have significant clinical benefits in the treatment of oral squamous cell carcinoma (OSCC). With the advancement of immunotherapy, an increasing number of ICIs have been developed or are in clinical trial stages. However, drug resistance and immune-related adverse events (irAEs) associated with ICIs have limited the clinical application of immunotherapy in OSCC, and the optimal drug regimen for ICIs and the optimal duration of ICIs administration also deserves to be further discussed. New therapeutic regimens and drug delivery technologies are key to promoting the further development of ICIs. This article elucidates the mechanism of ICIs’ action and presents a review of their clinical applications and current development status in OSCC. Additionally, it summarizes the current challenges and outlines future research directions for ICIs therapy, with the aim of offering fresh insights to researchers.
{"title":"Clinical applications and perspectives of immune checkpoint inhibitors in oral squamous cell carcinoma","authors":"Liuyu Ru, Jiwei Zheng","doi":"10.1515/oncologie-2024-0086","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0086","url":null,"abstract":"Abstract Immune checkpoint inhibitors (ICIs) promote antitumour immune responses by blocking inhibitory signals expressed by T cells and have significant clinical benefits in the treatment of oral squamous cell carcinoma (OSCC). With the advancement of immunotherapy, an increasing number of ICIs have been developed or are in clinical trial stages. However, drug resistance and immune-related adverse events (irAEs) associated with ICIs have limited the clinical application of immunotherapy in OSCC, and the optimal drug regimen for ICIs and the optimal duration of ICIs administration also deserves to be further discussed. New therapeutic regimens and drug delivery technologies are key to promoting the further development of ICIs. This article elucidates the mechanism of ICIs’ action and presents a review of their clinical applications and current development status in OSCC. Additionally, it summarizes the current challenges and outlines future research directions for ICIs therapy, with the aim of offering fresh insights to researchers.","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141358070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-06DOI: 10.1515/oncologie-2024-0098
Qingguo Zou, Guangjuan Kan, Y. Han, Minyan Wang, Xiaofeng Fu, Shanshan Liu, Jingjing Ye, Qingyi Xiang, Qiong Luo, Jiang Zhu
Abstract Objectives To explore the value of ultrasound-guided radiofrequency ablation combined with puncture and aspiration in the intrauterine treatment of fetal sacrococcygeal cystic and solid teratoma. Case presentation A 27-year-old pregnant woman was diagnosed with a cystic and solid tumor in the fetal sacrococcygeal region at 25 weeks of gestation. As the tumor grew, our clinical team creatively performed ultrasound-guided radiofrequency ablation combined with puncture and aspiration at 28 weeks of gestation, followed by puncture and aspiration only at 32 weeks of gestation, to reduce the tumor volume and control its growth rate. The fetus grew safely to term and underwent surgical excision of the tumor after 7 days of birth with a favorable prognosis. Conclusions Ultrasound-guided radiofrequency ablation combined with puncture and aspiration is a safe and effective method for the treatment of fetal sacrococcygeal cystic-solid teratoma.
{"title":"Ultrasound-guided radiofrequency ablation combined with puncture and aspiration for intrauterine treatment of fetal sacrococcygeal cystic solid teratoma: a case report and literature review","authors":"Qingguo Zou, Guangjuan Kan, Y. Han, Minyan Wang, Xiaofeng Fu, Shanshan Liu, Jingjing Ye, Qingyi Xiang, Qiong Luo, Jiang Zhu","doi":"10.1515/oncologie-2024-0098","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0098","url":null,"abstract":"Abstract Objectives To explore the value of ultrasound-guided radiofrequency ablation combined with puncture and aspiration in the intrauterine treatment of fetal sacrococcygeal cystic and solid teratoma. Case presentation A 27-year-old pregnant woman was diagnosed with a cystic and solid tumor in the fetal sacrococcygeal region at 25 weeks of gestation. As the tumor grew, our clinical team creatively performed ultrasound-guided radiofrequency ablation combined with puncture and aspiration at 28 weeks of gestation, followed by puncture and aspiration only at 32 weeks of gestation, to reduce the tumor volume and control its growth rate. The fetus grew safely to term and underwent surgical excision of the tumor after 7 days of birth with a favorable prognosis. Conclusions Ultrasound-guided radiofrequency ablation combined with puncture and aspiration is a safe and effective method for the treatment of fetal sacrococcygeal cystic-solid teratoma.","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141381536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A novel cell death pathway, disulfidptosis, marked by intracellular disulfide build-up, is a recently identified form of cell death. This study developed a dependable model using disulfidptosis-associated lncRNAs to predict outcomes and immune interactions in clear cell renal cell carcinoma (ccRCC) patients. Data from ccRCC patients, including genomic and clinicopathological details, were sourced from The Cancer Genome Atlas database. We employed the least absolute shrinkage and selection operator (LASSO) along with regression analyses to construct a prognostic model consisting of 12 disulfidptosis-related lncRNAs (DRLs). The model’s validity was tested using the RECA-EU and GSE29609 datasets. The prognostic model, incorporating 12 DRLs – LINC01671, DOCK9-DT, AL078581.2, SPINT1-AS1, ZNF503-AS1, AL391883.1, AC002070.1, AP001372.2, AC068338.3, AC026401.3, AL355835.1, and AL162377.1 – distinguished high-risk ccRCC patients with diminished survival rates in both the training and validation cohorts. Further analyses through Cox regression confirmed this risk model’s independent prognostic capability regarding overall survival (OS). Functional enrichment analysis indicated significant involvement of differentially expressed genes in immune response mediator production. A prognostic nomogram, integrating DRLs with clinical features, showed strong predictive accuracy as confirmed by receiver operating characteristic curves. Additionally, assessments of immune functionality and tumor mutation burden varied across risk categories in the tumor microenvironment, highlighting potential targets for anticancer drugs. The findings suggest the DRLs signature is a potent prognostic indicator and may serve to forecast responses to immunotherapy in ccRCC patients.
{"title":"Establishment of a prognostic signature of disulfidptosis-related lncRNAs for predicting survival and immune landscape in clear cell renal cell carcinoma","authors":"Jinhui Liu, Zhou Zhang, Lei Xiao, Yuhang Guo, Sheng Luo, Benzheng Zhou","doi":"10.1515/oncologie-2024-0049","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0049","url":null,"abstract":"\u0000 \u0000 \u0000 A novel cell death pathway, disulfidptosis, marked by intracellular disulfide build-up, is a recently identified form of cell death. This study developed a dependable model using disulfidptosis-associated lncRNAs to predict outcomes and immune interactions in clear cell renal cell carcinoma (ccRCC) patients.\u0000 \u0000 \u0000 \u0000 Data from ccRCC patients, including genomic and clinicopathological details, were sourced from The Cancer Genome Atlas database. We employed the least absolute shrinkage and selection operator (LASSO) along with regression analyses to construct a prognostic model consisting of 12 disulfidptosis-related lncRNAs (DRLs). The model’s validity was tested using the RECA-EU and GSE29609 datasets.\u0000 \u0000 \u0000 \u0000 The prognostic model, incorporating 12 DRLs – LINC01671, DOCK9-DT, AL078581.2, SPINT1-AS1, ZNF503-AS1, AL391883.1, AC002070.1, AP001372.2, AC068338.3, AC026401.3, AL355835.1, and AL162377.1 – distinguished high-risk ccRCC patients with diminished survival rates in both the training and validation cohorts. Further analyses through Cox regression confirmed this risk model’s independent prognostic capability regarding overall survival (OS). Functional enrichment analysis indicated significant involvement of differentially expressed genes in immune response mediator production. A prognostic nomogram, integrating DRLs with clinical features, showed strong predictive accuracy as confirmed by receiver operating characteristic curves. Additionally, assessments of immune functionality and tumor mutation burden varied across risk categories in the tumor microenvironment, highlighting potential targets for anticancer drugs.\u0000 \u0000 \u0000 \u0000 The findings suggest the DRLs signature is a potent prognostic indicator and may serve to forecast responses to immunotherapy in ccRCC patients.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141270940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-27DOI: 10.1515/oncologie-2024-0071
Jun Zhang, Jiejie He, Wen Chen, Guojun Chen, Liang Wang, Yuchan Liu, Zhanjin Wang, Ming Yang, Guoyi Huang, Yongli Yang, Wei Ma, Yan Li
Bladder carcinoma (BC) is a common malignancy of the urinary tract. As a new hallmark of cancer for drug therapy, RNA-binding proteins (RBPs) are key regulatory factors in alternative splicing events. This work is to uncover the relationship between BC and RBP in order to find drug targets in BC. In this work, data from single-cell RNA-seq GSE1355337, PRJNA662018, and the TCGA-Bladder urothelial carcinoma (BLCA) cohorts are integrated to identify their relationships. A scoring system is constructed according to RBPs gene expression and patients’ survival. A network is constructed to analyze the alternative splicing events and RBP genes. A scoring system identified 321 RBPs significantly associated with the prognosis of patients. Subsequent typing of these RBP genes in two single-cell datasets demonstrated that most of the RBP genes had variable copy numbers. Three RBP clusters were identified. Using RBP genes as a signature in BC epithelial cells allows for differentiation between different grades of BC samples. The novel RBP genes-based subtype system reflects BC clinical staging. Notably, CellChat analysis revealed that the RBP genes-associated cell subtypes of T cells had extensive interactions with epithelial cells. Further analysis showed that the ligand-receptor pair MIF-CXCR4 mediated the communication between RBP-associated subtypes of BC epithelial cells and T cells. Taken together, RBP genes are associated with BC progress and offer new indicators for precision medicine in BC.
膀胱癌（BC）是一种常见的泌尿系统恶性肿瘤。RNA结合蛋白（RBPs）是药物治疗癌症的新标志，是替代剪接事件的关键调控因子。这项工作旨在揭示 BC 与 RBP 之间的关系，从而找到 BC 的药物靶点。 在这项工作中，我们整合了来自单细胞 RNA 序列 GSE1355337、PRJNA662018 和 TCGA 膀胱尿道癌（BLCA）队列的数据，以确定它们之间的关系。根据 RBPs 基因表达和患者生存率构建了一个评分系统。构建了一个网络来分析替代剪接事件和 RBP 基因。 评分系统确定了 321 个与患者预后明显相关的 RBPs。随后在两个单细胞数据集中对这些RBP基因进行了分型，结果表明大多数RBP基因的拷贝数是可变的。结果发现了三个 RBP 群。利用 BC 上皮细胞中的 RBP 基因作为特征，可以区分不同等级的 BC 样本。基于RBP基因的新型亚型系统反映了BC临床分期。值得注意的是，CellChat 分析显示，与 RBP 基因相关的 T 细胞亚型与上皮细胞有广泛的相互作用。进一步的分析表明，配体-受体对 MIF-CXCR4 介导了 RBP 相关亚型 BC 上皮细胞与 T 细胞之间的交流。 综上所述，RBP基因与BC进展相关，为BC的精准医疗提供了新的指标。
{"title":"Single-cell RNA-binding protein pattern-mediated molecular subtypes depict the hallmarks of the tumor microenvironment in bladder urothelial carcinoma","authors":"Jun Zhang, Jiejie He, Wen Chen, Guojun Chen, Liang Wang, Yuchan Liu, Zhanjin Wang, Ming Yang, Guoyi Huang, Yongli Yang, Wei Ma, Yan Li","doi":"10.1515/oncologie-2024-0071","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0071","url":null,"abstract":"\u0000 \u0000 \u0000 Bladder carcinoma (BC) is a common malignancy of the urinary tract. As a new hallmark of cancer for drug therapy, RNA-binding proteins (RBPs) are key regulatory factors in alternative splicing events. This work is to uncover the relationship between BC and RBP in order to find drug targets in BC.\u0000 \u0000 \u0000 \u0000 In this work, data from single-cell RNA-seq GSE1355337, PRJNA662018, and the TCGA-Bladder urothelial carcinoma (BLCA) cohorts are integrated to identify their relationships. A scoring system is constructed according to RBPs gene expression and patients’ survival. A network is constructed to analyze the alternative splicing events and RBP genes.\u0000 \u0000 \u0000 \u0000 A scoring system identified 321 RBPs significantly associated with the prognosis of patients. Subsequent typing of these RBP genes in two single-cell datasets demonstrated that most of the RBP genes had variable copy numbers. Three RBP clusters were identified. Using RBP genes as a signature in BC epithelial cells allows for differentiation between different grades of BC samples. The novel RBP genes-based subtype system reflects BC clinical staging. Notably, CellChat analysis revealed that the RBP genes-associated cell subtypes of T cells had extensive interactions with epithelial cells. Further analysis showed that the ligand-receptor pair MIF-CXCR4 mediated the communication between RBP-associated subtypes of BC epithelial cells and T cells.\u0000 \u0000 \u0000 \u0000 Taken together, RBP genes are associated with BC progress and offer new indicators for precision medicine in BC.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-22DOI: 10.1515/oncologie-2024-0027
N. Dinh Hieu, N. Duy Hung, L. Thanh Dung, Nguyen Ngoc Anh, N. M. Minh Duc
Determining the grade of a glioma is extremely important for treatment planning and prognosis prediction. The study aimed to evaluate the usefulness of multiparametric perfusion-weighted imaging (PWI) and diffusion-weighted imaging (DWI) in preoperative glioma grading. In this retrospective study, 63 individuals with brain tumors histologically confirmed, of which 23 had low-grade gliomas (LGGs) and 40 had high-grade gliomas (HGGs) were involved. We conducted this paper on apparent diffusion coefficient (ADC) maps using the entire tumor volume method, allowing us to use all ADC values of the tumor. Small-sample regions of interest (ROIs) were drawn to collect parameters of relative cerebral blood flow (rCBF), cerebral blood flow (CBF), and relative cerebral blood volume (rCBV), from both the tumor core and peritumoral edema. The PWI and DWI metrics were compared to identify the most accurate distinguishing HGGs and LGGs, analyze receiver operating characteristics (ROC), and evaluate the diagnostic performance using solitary parameters and combined. In diffusion MRI, there were significant differences in minimum ADC and mean ADC between LGGs and HGGs (p<0.05), with the larger area under the curve (AUC) of 0.898 found for mean ADC at a cut-off value of 1.275, with sensitivity of 82.6 % and specificity of 90 %. The maximum ADC value did not differ significantly (p>0.05). All perfusion parameters in both the tumor core and peritumoral edema area were significantly greater values in cases of HGG compared to LGG (p<0.001), with the highest AUC of 0.946 found for solid tumor rCBV value (rCBVt), the cut-off is 3.585, sensitivity of 85 % and specificity of 100 %. Combining mean ADC and rCBVt provided an excellent AUC of 0.975, a sensitivity of 92.5 %, and a specificity of 91.3 % for differentiating between HGGs and LGGs. Perfusion and diffusion MRI are valuable in discriminating between high-grade and low-grade gliomas, with the major criterion in the decision-making process being the combined mean ADC and rCBVt parameters.
{"title":"The impact of diffusion and perfusion-weighted imaging on glioma grading","authors":"N. Dinh Hieu, N. Duy Hung, L. Thanh Dung, Nguyen Ngoc Anh, N. M. Minh Duc","doi":"10.1515/oncologie-2024-0027","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0027","url":null,"abstract":"\u0000 \u0000 \u0000 Determining the grade of a glioma is extremely important for treatment planning and prognosis prediction. The study aimed to evaluate the usefulness of multiparametric perfusion-weighted imaging (PWI) and diffusion-weighted imaging (DWI) in preoperative glioma grading.\u0000 \u0000 \u0000 \u0000 In this retrospective study, 63 individuals with brain tumors histologically confirmed, of which 23 had low-grade gliomas (LGGs) and 40 had high-grade gliomas (HGGs) were involved. We conducted this paper on apparent diffusion coefficient (ADC) maps using the entire tumor volume method, allowing us to use all ADC values of the tumor. Small-sample regions of interest (ROIs) were drawn to collect parameters of relative cerebral blood flow (rCBF), cerebral blood flow (CBF), and relative cerebral blood volume (rCBV), from both the tumor core and peritumoral edema. The PWI and DWI metrics were compared to identify the most accurate distinguishing HGGs and LGGs, analyze receiver operating characteristics (ROC), and evaluate the diagnostic performance using solitary parameters and combined.\u0000 \u0000 \u0000 \u0000 In diffusion MRI, there were significant differences in minimum ADC and mean ADC between LGGs and HGGs (p<0.05), with the larger area under the curve (AUC) of 0.898 found for mean ADC at a cut-off value of 1.275, with sensitivity of 82.6 % and specificity of 90 %. The maximum ADC value did not differ significantly (p>0.05). All perfusion parameters in both the tumor core and peritumoral edema area were significantly greater values in cases of HGG compared to LGG (p<0.001), with the highest AUC of 0.946 found for solid tumor rCBV value (rCBVt), the cut-off is 3.585, sensitivity of 85 % and specificity of 100 %. Combining mean ADC and rCBVt provided an excellent AUC of 0.975, a sensitivity of 92.5 %, and a specificity of 91.3 % for differentiating between HGGs and LGGs.\u0000 \u0000 \u0000 \u0000 Perfusion and diffusion MRI are valuable in discriminating between high-grade and low-grade gliomas, with the major criterion in the decision-making process being the combined mean ADC and rCBVt parameters.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141109900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-22DOI: 10.1515/oncologie-2024-0101
Hong Qiu, Zhaorong Tang, Dan Nie
Primary renal synovial sarcoma (PRSS) is an uncommon malignancy with diagnostic challenges and poor prognosis. Research on PRSS is limited, primarily based on case reports, leading to a lack of widely recognized effective treatment options. This article reports a case of primary renal synovial sarcoma diagnosed using a novel fusion gene with a fusion site involving the SS18 and SSX2 exons. A 34-year-old male, presented with intermittent right upper abdominal pain. Abdominal CT revealed an isolated mass in the upper pole of the right kidney, which was initially diagnosed as renal cell carcinoma. The patient underwent radical right nephrectomy, and postoperative histopathological examination confirmed the diagnosis of synovial sarcoma, and immunohistochemistry supported the diagnosis. Further detection through RT-PCR and DNA sequencing confirmed the presence of the SS18-SSX2 fusion gene. Despite the recommendation for adjuvant therapy, the patient refused chemotherapy and other treatments and succumbed to systemic metastasis. This case highlights the diagnostic challenges and aggressive nature of PRSS. The novel fusion gene with the fusion sites SS18: exon9 and SSX2: exon5 has important implications for the diagnosis of primary synovial sarcoma of the kidney. Further research is warranted to explore novel therapeutic strategies and improve patient outcomes in PRSS.
{"title":"Primary renal synovial sarcomas diagnosed by a novel fusion gene with the fusion site involving exons of SS18 and SSX2: a case report","authors":"Hong Qiu, Zhaorong Tang, Dan Nie","doi":"10.1515/oncologie-2024-0101","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0101","url":null,"abstract":"\u0000 \u0000 \u0000 Primary renal synovial sarcoma (PRSS) is an uncommon malignancy with diagnostic challenges and poor prognosis. Research on PRSS is limited, primarily based on case reports, leading to a lack of widely recognized effective treatment options. This article reports a case of primary renal synovial sarcoma diagnosed using a novel fusion gene with a fusion site involving the SS18 and SSX2 exons.\u0000 \u0000 \u0000 \u0000 A 34-year-old male, presented with intermittent right upper abdominal pain. Abdominal CT revealed an isolated mass in the upper pole of the right kidney, which was initially diagnosed as renal cell carcinoma. The patient underwent radical right nephrectomy, and postoperative histopathological examination confirmed the diagnosis of synovial sarcoma, and immunohistochemistry supported the diagnosis. Further detection through RT-PCR and DNA sequencing confirmed the presence of the SS18-SSX2 fusion gene. Despite the recommendation for adjuvant therapy, the patient refused chemotherapy and other treatments and succumbed to systemic metastasis.\u0000 \u0000 \u0000 \u0000 This case highlights the diagnostic challenges and aggressive nature of PRSS. The novel fusion gene with the fusion sites SS18: exon9 and SSX2: exon5 has important implications for the diagnosis of primary synovial sarcoma of the kidney. Further research is warranted to explore novel therapeutic strategies and improve patient outcomes in PRSS.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141112737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-22DOI: 10.1515/oncologie-2024-0095
Jie Sheng, Zihan Zheng, Xuejuan Li, Meijing Li, Feng Zheng
The prognosis of clear cell renal cell carcinoma (ccRCC) is typically based on clinical stage, but it can vary for some patients. Transcriptomic analysis is vital for understanding ccRCC progression, though its correlation with the clinical stage in predicting prognosis is uncertain. We aim to employ trajectory inference to study ccRCC’s molecular progression and identify potential new markers for judging disease progression and prognosis. Using a trajectory inference approach, we characterize the molecular progression profile of ccRCC based on transcriptome profiling. Additional pathway activity, immune response, and miRNA profiling scoring were integrated to identify possible drivers of trajectory progression. Scoring based on the trajectory demonstrates a significant improvement in patient prognosis prediction and identifies 10 risk factors in patients with low-grade tumors, and nine protective factors in patients with high-grade tumors. Mechanistically, we demonstrate an association between solute light carrier transporters are associated with ccRCC progression, with SLC7A5 expression being validated through immunohistochemistry to increase in metastatic patients. Trajectory analysis of ccRCC transcriptomes can be used to model the molecular progression of disease and may assist in ccRCC prognosis. SLC7A5 is aberrantly expressed in ccRCC and may be a risk factor for poor prognosis.
{"title":"Trajectory mapping of renal clear cell carcinoma transcriptomes identifies stage-independent predictors of favorable prognosis","authors":"Jie Sheng, Zihan Zheng, Xuejuan Li, Meijing Li, Feng Zheng","doi":"10.1515/oncologie-2024-0095","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0095","url":null,"abstract":"\u0000 \u0000 \u0000 The prognosis of clear cell renal cell carcinoma (ccRCC) is typically based on clinical stage, but it can vary for some patients. Transcriptomic analysis is vital for understanding ccRCC progression, though its correlation with the clinical stage in predicting prognosis is uncertain. We aim to employ trajectory inference to study ccRCC’s molecular progression and identify potential new markers for judging disease progression and prognosis.\u0000 \u0000 \u0000 \u0000 Using a trajectory inference approach, we characterize the molecular progression profile of ccRCC based on transcriptome profiling. Additional pathway activity, immune response, and miRNA profiling scoring were integrated to identify possible drivers of trajectory progression.\u0000 \u0000 \u0000 \u0000 Scoring based on the trajectory demonstrates a significant improvement in patient prognosis prediction and identifies 10 risk factors in patients with low-grade tumors, and nine protective factors in patients with high-grade tumors. Mechanistically, we demonstrate an association between solute light carrier transporters are associated with ccRCC progression, with SLC7A5 expression being validated through immunohistochemistry to increase in metastatic patients.\u0000 \u0000 \u0000 \u0000 Trajectory analysis of ccRCC transcriptomes can be used to model the molecular progression of disease and may assist in ccRCC prognosis. SLC7A5 is aberrantly expressed in ccRCC and may be a risk factor for poor prognosis.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141109889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-15DOI: 10.1515/oncologie-2023-0319
Weiguo Hu, Jie Zhang, Dingyi Zhou, Shu Xia, Xingxiang Pu, Jianzhong Cao, Mingzhu Zou, Zhangfan Mao, Qibin Song, Xiaodong Zhang
To compare and evaluate the performance of artificial intelligence (AI) against physicians in classifying benign and malignant pulmonary nodules from computerized tomography (CT) images. A total of 506 CT images with pulmonary nodules were retrospectively collected. The AI was trained using in-house software. For comparing the diagnostic performance of artificial intelligence and different groups of physicians in pulmonary nodules, statistical methods of receiver operating characteristic (ROC) curve and area under the curve (AUC) were analyzed. The nodules in CT images were analyzed in a case-by-case manner. The diagnostic accuracy of AI surpassed that of all groups of physicians, exhibiting an AUC of 0.88 alongside a sensitivity of 0.80, specificity of 0.84, and accuracy of 0.83. The area under the curve (AUC) of seven groups of physicians varies between 0.63 and 0.84. The sensitivity of the physicians within these groups varies between 0.4 and 0.76. The specificity of different groups ranges from 0.8 to 0.85. Furthermore, the accuracy of the seven groups ranges from 0.7 to 0.82. The professional insights for enhancing deep learning models were obtained through an examination conducted on a per-case basis. AI demonstrated great potential in the benign–malignant classification of pulmonary nodules with higher accuracy. More accurate information will be provided by AI when making clinical decisions.
{"title":"A comparison study of artificial intelligence performance against physicians in benign–malignant classification of pulmonary nodules","authors":"Weiguo Hu, Jie Zhang, Dingyi Zhou, Shu Xia, Xingxiang Pu, Jianzhong Cao, Mingzhu Zou, Zhangfan Mao, Qibin Song, Xiaodong Zhang","doi":"10.1515/oncologie-2023-0319","DOIUrl":"https://doi.org/10.1515/oncologie-2023-0319","url":null,"abstract":"\u0000 \u0000 \u0000 To compare and evaluate the performance of artificial intelligence (AI) against physicians in classifying benign and malignant pulmonary nodules from computerized tomography (CT) images.\u0000 \u0000 \u0000 \u0000 A total of 506 CT images with pulmonary nodules were retrospectively collected. The AI was trained using in-house software. For comparing the diagnostic performance of artificial intelligence and different groups of physicians in pulmonary nodules, statistical methods of receiver operating characteristic (ROC) curve and area under the curve (AUC) were analyzed. The nodules in CT images were analyzed in a case-by-case manner.\u0000 \u0000 \u0000 \u0000 The diagnostic accuracy of AI surpassed that of all groups of physicians, exhibiting an AUC of 0.88 alongside a sensitivity of 0.80, specificity of 0.84, and accuracy of 0.83. The area under the curve (AUC) of seven groups of physicians varies between 0.63 and 0.84. The sensitivity of the physicians within these groups varies between 0.4 and 0.76. The specificity of different groups ranges from 0.8 to 0.85. Furthermore, the accuracy of the seven groups ranges from 0.7 to 0.82. The professional insights for enhancing deep learning models were obtained through an examination conducted on a per-case basis.\u0000 \u0000 \u0000 \u0000 AI demonstrated great potential in the benign–malignant classification of pulmonary nodules with higher accuracy. More accurate information will be provided by AI when making clinical decisions.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140976649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Crebanine, an alkaloid exhibiting sedative, anti-inflammatory, and anticancer properties, remains unexplored in terms of its anticancer potential against colorectal cancer (CRC). This study aims to bridge this knowledge gap, specifically investigating whether crebanine can suppress CRC and elucidating its underlying molecular mechanism. We employed the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay, cell scratch assay, and flow cytometry to observe the effects of crebanine on the growth, migration, and apoptosis of CRC SW480 cells, respectively. High-throughput sequencing was employed to detect differentially expressed genes (DEGs) in SW480 cells treated with crebanine. Enriched pathways of these DEGs were identified through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Genes exhibiting the highest correlation in the enriched pathway were further analyzed using clinical data from The Cancer Genome Atlas Program (TCGA) public database, utilizing R software. Crebanine effectively inhibited the proliferation, migration, and invasion of SW480 cells, with concentrations of ≥15 μg/mL promoting apoptosis. Analysis revealed that the function of DEGs linked to the most enriched pathways was associated with immune infiltration by regulatory T cells (Tregs). When analyzed in conjunction with clinical data, the genes exhibiting the highest correlation in the enrichment pathway were found to be directly associated with clinical prognostic survival. Our study demonstrates that crebanine inhibits colorectal cancer by regulating prognostic target genes related to Tregs. This finding offers a novel approach for pharmacological inhibition and Tregs-targeted therapy in CRC.
{"title":"High-throughput sequencing reveals crebanine inhibits colorectal cancer by modulating Tregs immune prognostic target genes","authors":"Jiajun Xu, Lingyu Huang, Yu Sha, Chune Mo, Weiwei Gong, Xiayu Tian, Xianliang Hou, Wei Chen, Minglin Ou","doi":"10.1515/oncologie-2024-0073","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0073","url":null,"abstract":"\u0000 \u0000 \u0000 Crebanine, an alkaloid exhibiting sedative, anti-inflammatory, and anticancer properties, remains unexplored in terms of its anticancer potential against colorectal cancer (CRC). This study aims to bridge this knowledge gap, specifically investigating whether crebanine can suppress CRC and elucidating its underlying molecular mechanism.\u0000 \u0000 \u0000 \u0000 We employed the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay, cell scratch assay, and flow cytometry to observe the effects of crebanine on the growth, migration, and apoptosis of CRC SW480 cells, respectively. High-throughput sequencing was employed to detect differentially expressed genes (DEGs) in SW480 cells treated with crebanine. Enriched pathways of these DEGs were identified through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Genes exhibiting the highest correlation in the enriched pathway were further analyzed using clinical data from The Cancer Genome Atlas Program (TCGA) public database, utilizing R software.\u0000 \u0000 \u0000 \u0000 Crebanine effectively inhibited the proliferation, migration, and invasion of SW480 cells, with concentrations of ≥15 μg/mL promoting apoptosis. Analysis revealed that the function of DEGs linked to the most enriched pathways was associated with immune infiltration by regulatory T cells (Tregs). When analyzed in conjunction with clinical data, the genes exhibiting the highest correlation in the enrichment pathway were found to be directly associated with clinical prognostic survival.\u0000 \u0000 \u0000 \u0000 Our study demonstrates that crebanine inhibits colorectal cancer by regulating prognostic target genes related to Tregs. This finding offers a novel approach for pharmacological inhibition and Tregs-targeted therapy in CRC.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140972030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-13DOI: 10.1515/oncologie-2024-0074
Shenglin Gao, Xiaokai Shi, C. Yue, Yin Chen, Li Zuo, Simin Wang
This study aims to elucidate the role of competing endogenous RNAs (ceRNAs), which are pivotal in the post-transcriptional regulation of cancer cells, in the glycolysis of clear cell renal cell carcinoma (ccRCC). RNA-seq data from ccRCC samples and public datasets were subjected to differential expression analysis to identify the upregulated circular RNAs (circRNAs), long noncoding RNAs (lncRNAs), and mRNAs for constructing a ceRNA network. This network focused on the upregulated mRNAs linked to glycolysis and gluconeogenesis, which were verified at the proteome level using the CPTAC database. The ENCORI database was used to predict the lncRNA/circRNA-miRNA and miRNA-mRNA interactions, which formed a network visualized using Cytoscape. This study further examined the association of selected lncRNAs/circRNAs with biological processes and patient survival and explored lncRNA and mRNA expressions at the single-cell level. Three circRNAs and eight lncRNAs were identified to be regulators of four glycolysis pathway genes (HK2, LDHA, PFKP, and ALDOC) via 54 miRNAs. Notably, their expressions were aberrant at the transcriptome and proteome levels. These RNA elements were correlated with malignant and immune pathways, and several lncRNAs showed prognostic significance for ccRCC. Furthermore, single-cell RNA sequencing indicated the abnormal enrichment of these lncRNAs and mRNAs in malignant cells. This study identified a ceRNA network that plays a critical role in the glycolysis of ccRCC. These findings highlight the importance of ceRNAs in cancer malignancy and their potential impact on patient prognosis.
{"title":"Comprehensive analysis of competing endogenous RNA networks involved in the regulation of glycolysis in clear cell renal cell carcinoma","authors":"Shenglin Gao, Xiaokai Shi, C. Yue, Yin Chen, Li Zuo, Simin Wang","doi":"10.1515/oncologie-2024-0074","DOIUrl":"https://doi.org/10.1515/oncologie-2024-0074","url":null,"abstract":"\u0000 \u0000 \u0000 This study aims to elucidate the role of competing endogenous RNAs (ceRNAs), which are pivotal in the post-transcriptional regulation of cancer cells, in the glycolysis of clear cell renal cell carcinoma (ccRCC).\u0000 \u0000 \u0000 \u0000 RNA-seq data from ccRCC samples and public datasets were subjected to differential expression analysis to identify the upregulated circular RNAs (circRNAs), long noncoding RNAs (lncRNAs), and mRNAs for constructing a ceRNA network. This network focused on the upregulated mRNAs linked to glycolysis and gluconeogenesis, which were verified at the proteome level using the CPTAC database. The ENCORI database was used to predict the lncRNA/circRNA-miRNA and miRNA-mRNA interactions, which formed a network visualized using Cytoscape. This study further examined the association of selected lncRNAs/circRNAs with biological processes and patient survival and explored lncRNA and mRNA expressions at the single-cell level.\u0000 \u0000 \u0000 \u0000 Three circRNAs and eight lncRNAs were identified to be regulators of four glycolysis pathway genes (HK2, LDHA, PFKP, and ALDOC) via 54 miRNAs. Notably, their expressions were aberrant at the transcriptome and proteome levels. These RNA elements were correlated with malignant and immune pathways, and several lncRNAs showed prognostic significance for ccRCC. Furthermore, single-cell RNA sequencing indicated the abnormal enrichment of these lncRNAs and mRNAs in malignant cells.\u0000 \u0000 \u0000 \u0000 This study identified a ceRNA network that plays a critical role in the glycolysis of ccRCC. These findings highlight the importance of ceRNAs in cancer malignancy and their potential impact on patient prognosis.\u0000","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140982279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：